JP2011136997A5 - - Google Patents

Download PDF

Info

Publication number
JP2011136997A5
JP2011136997A5 JP2011000275A JP2011000275A JP2011136997A5 JP 2011136997 A5 JP2011136997 A5 JP 2011136997A5 JP 2011000275 A JP2011000275 A JP 2011000275A JP 2011000275 A JP2011000275 A JP 2011000275A JP 2011136997 A5 JP2011136997 A5 JP 2011136997A5
Authority
JP
Japan
Prior art keywords
nucleic acid
protein
nucleotide sequence
mammal
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011000275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011136997A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011136997A publication Critical patent/JP2011136997A/ja
Publication of JP2011136997A5 publication Critical patent/JP2011136997A5/ja
Withdrawn legal-status Critical Current

Links

JP2011000275A 2003-09-17 2011-01-04 コンセンサス／先祖免疫原 Withdrawn JP2011136997A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50346003P 2003-09-17 2003-09-17
US60/503,460 2003-09-17
US60472204P 2004-08-27 2004-08-27
US60/604,722 2004-08-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006527030A Division JP4773352B2 (ja) 2003-09-17 2004-09-17 コンセンサス／先祖免疫原

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013253689A Division JP6165612B2 (ja) 2003-09-17 2013-12-06 コンセンサス／先祖免疫原

Publications (2)

Publication Number Publication Date
JP2011136997A JP2011136997A (ja) 2011-07-14
JP2011136997A5 true JP2011136997A5 (enExample) 2011-08-25

Family

ID=34381074

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006527030A Expired - Fee Related JP4773352B2 (ja) 2003-09-17 2004-09-17 コンセンサス／先祖免疫原
JP2011000275A Withdrawn JP2011136997A (ja) 2003-09-17 2011-01-04 コンセンサス／先祖免疫原
JP2013253689A Expired - Fee Related JP6165612B2 (ja) 2003-09-17 2013-12-06 コンセンサス／先祖免疫原

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006527030A Expired - Fee Related JP4773352B2 (ja) 2003-09-17 2004-09-17 コンセンサス／先祖免疫原

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013253689A Expired - Fee Related JP6165612B2 (ja) 2003-09-17 2013-12-06 コンセンサス／先祖免疫原

Country Status (10)

Country Link
US (3) US8071107B2 (enExample)
EP (2) EP1667714B1 (enExample)
JP (3) JP4773352B2 (enExample)
KR (2) KR20070028291A (enExample)
CN (2) CN102010463A (enExample)
AU (1) AU2004274937B9 (enExample)
BR (1) BRPI0414443A (enExample)
CA (2) CA2539325C (enExample)
IL (3) IL174380A0 (enExample)
WO (1) WO2005028625A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1635876A (zh) 2000-02-04 2005-07-06 杜克大学 人免疫缺陷病毒疫苗
US7033593B2 (en) 2000-09-22 2006-04-25 Duke University Immunogen comprising an HIV envelope protein, a ligand and H2 peptide
EP1331942A4 (en) 2000-09-22 2005-03-16 Univ Duke Immunogenic with ligand-bound HIV envelope protein
US8048431B2 (en) * 2003-09-17 2011-11-01 Duke University Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
CA2539325C (en) 2003-09-17 2016-03-22 Duke University Consensus/ancestral immunogens
EP2295973A1 (en) 2004-09-08 2011-03-16 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Compositions and methods for the detection of HIV-1/HIV-2 infection.
US8119140B2 (en) 2005-08-23 2012-02-21 Los Alamos Security, LLC Immunogenic compositions comprising human immunodeficiency virus (HIV) mosaic Nef proteins
US7951377B2 (en) * 2005-08-23 2011-05-31 Los Alamos National Security, Llc Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens
SG170092A1 (en) * 2006-03-10 2011-04-29 Peptcell Ltd Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof
CA2648086C (en) 2006-03-29 2014-05-13 Dana Farber Cancer Institute, Inc. Methods and compositions for inducing an immune response to hiv and models for testing
AU2007256717B2 (en) * 2006-06-02 2013-06-20 International Aids Vaccine Initiative HIV-1 Clade A consensus sequences, antigens, and transgenes
AU2015234338C1 (en) * 2006-07-28 2017-07-20 The Trustees Of The University Of Pennsylvania Improved vaccines and methods for using the same
KR102511874B1 (ko) * 2006-07-28 2023-03-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 백신 및 이의 사용 방법
JP2010530356A (ja) * 2007-03-27 2010-09-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 急性伝染ｈｉｖエンベロープ・サイン
PL2358757T3 (pl) 2008-11-18 2019-02-28 Beth Israel Deaconess Medical Center Szczepionki antywirusowe o ulepszonej immunogenności komórkowej
JP2013520498A (ja) * 2010-02-25 2013-06-06 デューク ユニバーシティー 防御的抗ｈｉｖ−１抗体の産生を誘導する方法
US20130177583A1 (en) * 2010-03-03 2013-07-11 Duke University Molecular clone of hiv-1
WO2012047267A2 (en) * 2010-09-28 2012-04-12 Duke University Polyvalent immunogen
EP2492279A1 (en) * 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
US10040826B2 (en) 2011-07-05 2018-08-07 Duke University Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens
EP2763699A4 (en) * 2011-10-03 2015-05-20 Univ Duke VACCINE
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
EP2820035B1 (en) 2012-03-02 2019-01-09 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Method of altering the immundominance hierarchy of hiv gag by dna vaccine expressing conserved regions
US20150265695A1 (en) * 2012-07-24 2015-09-24 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
KR101826536B1 (ko) 2012-08-07 2018-02-07 현대자동차 주식회사 차량의 아이들 스톱 제어 방법 및 장치
WO2014151687A2 (en) 2013-03-15 2014-09-25 University Of Massachusetts Compositions and methods to treat aids
EP3058065B1 (en) * 2013-10-16 2018-05-02 New England Biolabs, Inc. Reverse transcriptase with enhanced properties
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
WO2017007646A1 (en) * 2015-07-07 2017-01-12 International Aids Vaccine Initiative Hiv-1 clade c envelope glycoproteins
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
CA3016352A1 (en) 2016-03-03 2017-09-08 Duke University Compositions and methods for inducing hiv-1 antibodies
JP7178344B2 (ja) * 2016-09-15 2022-11-25 ヤンセン ファッシンズ アンド プリベンション ベーフェー 三量体安定化ｈｉｖエンベロープタンパク質変異
US10828363B1 (en) * 2016-09-16 2020-11-10 The Trustees Of The University Of Pennsylvania Extreme polyvalency induces potent cross-clade cellular and humoral responses in rabbits and non-human primates
EP3519428A4 (en) 2016-10-03 2020-07-08 Duke University METHODS OF IDENTIFYING IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS
EP3526236B1 (en) 2016-10-17 2025-12-10 Beth Israel Deaconess Medical Center, Inc. Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
US12138304B2 (en) 2018-10-01 2024-11-12 Duke University HIV-1 envelope stabilizing mutations
GB201816873D0 (en) * 2018-10-17 2018-11-28 Imperial Innovations Ltd Fusion protein
CN113924114A (zh) 2019-05-22 2022-01-11 吉利德科学公司 Tlr7调节化合物和hiv疫苗的组合
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
AU2020384323A1 (en) 2019-11-14 2022-06-02 Aelix Therapeutics, S.L. Dosage regimens for vaccines
CA3202466A1 (en) 2021-01-14 2022-07-21 Jiani LI Hiv vaccines and methods of using
CA3246969A1 (en) * 2022-03-31 2023-10-05 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. IMMUNOGENS AND HIV VACCINE COMPOSITIONS
WO2025072797A2 (en) * 2023-09-27 2025-04-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Immunogens and vaccine compositions against hiv

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US20030096778A1 (en) * 2002-06-13 2003-05-22 Shiver John W Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
CA2402440A1 (en) 2000-02-18 2001-08-23 University Of Washington Aids ancestral viruses and vaccines
US7655774B2 (en) 2000-02-18 2010-02-02 University Of Washington Ancestral and COT viral sequences, proteins and immunogenic compositions
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
EP1331942A4 (en) 2000-09-22 2005-03-16 Univ Duke Immunogenic with ligand-bound HIV envelope protein
US7172761B2 (en) 2001-11-07 2007-02-06 Duke University Polyvalent immunogen
US8048431B2 (en) 2003-09-17 2011-11-01 Duke University Modified HIV-1 clade C envelope glycoprotein immunogens comprising deletions in the gp120/gp41 cleavage site and gp41 fusion domain
CA2539325C (en) 2003-09-17 2016-03-22 Duke University Consensus/ancestral immunogens
HRP20040589B1 (en) 2004-06-28 2011-07-31 Biljan Marijan The stand for garment hangers with a built-in counter

Similar Documents

Publication Publication Date Title
JP2011530309A5 (enExample)
JP2012126742A5 (enExample)
JP2013172734A5 (enExample)
JP2011155981A5 (enExample)
JP2014513951A5 (enExample)
EP4303232A3 (en) Chimeric antigen receptor and methods of use thereof
HUE055505T2 (hu) Anti-CGRP készítmények és alkalmazásuk
HUE053720T2 (hu) ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra
BR112013012555A2 (pt) peptídeos imunogênicos para o uso na prevenção e/ou no tratamento de doenças infecciosas, doenças autoimunes, respostas imunes a alofatores, doenças alérgicas, tumores, rejeição a enxertos e respostas imunes contra vetores virais usados para a terapia de genes ou na vacinação de genes
CO7151522A2 (es) Proteínas de fusión de interleuquina-10 y usos de las mismas
CL2013002361A1 (es) Metodo para medir actividad de células natural killer (nk); kit para medir dicha actividad; proteína de fusión; composicion para activar células nk; polipéptido, oligonucleótido, vector y célula hospedera que comprenden la proteína;
PH12014502274A1 (en) Anti-fcrn antibodies
HUE047874T2 (hu) Vér dendritikus sejt antigén 2 elleni antitestek és alkalmazásuk
MX2013007918A (es) Peptidos inmunogenicos monomericos y multimericos.
CL2012002016A1 (es) Vector para vacunas que comprende un polipeptido antigénico y un polipéptido hmgb1 o un fragmento funcional; composición que comprende el vector; método para potenciar respuesta inmune en un sujeto.
ZA201306009B (en) Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same
SG11201502113YA (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
PL2776460T3 (pl) Białko fuzyjne zawierające interleukinę 4 i interleukinę 10
IN2012DN03209A (enExample)
BR112013018742A2 (pt) cya-transportador de polipeptídeo(s) e use para induzir tanto as terapias e resposta imunitária profilática
HUE050438T2 (hu) Rekombináns fehérjék és terápiás alkalmazásuk
WO2011094357A8 (en) Respiratory virus epitopes templated into double stranded coiled -coils and use thereof in immunization
MX2022003664A (es) Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion.
EP2528939A4 (en) RECOMBINANT PROTEINS FOR USE IN VACCINES, ANTIBODIES TO THESE PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC PROCEDURES THEREWITH
JP2013100370A5 (enExample)